v3.24.0.1
Consolidated Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings (accumulated deficit)
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2020 $ 13,097 $ 18 $ (2,264) $ 17,384 $ 1,055 $ (3,117) $ 21
Beginning balance (in shares) at Dec. 31, 2020   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 11,542 $ 0 0 0 11,542 0 0
Other comprehensive income, net of tax 218 0 0 0 0 218 0
Dividends declared (9,470) 0 0 0 (9,470) 0 0
Purchases of treasury stock (934) $ 0 (934) 0 0 0 0
Purchases of treasury stock (in shares)   (8)          
Stock-based compensation plans and other 976 $ 0 55 921 0 0 0
Stock-based compensation plans and other (in shares)   11          
Change in noncontrolling interest 7 $ 0 0 0 0 0 7
Ending balance at Dec. 31, 2021 15,436 $ 18 (3,143) 18,305 3,127 (2,899) 28
Ending balance (in shares) at Dec. 31, 2021   1,768          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 11,836 $ 0 0 0 11,836 0 0
Other comprehensive income, net of tax 700 0 0 0 0 700 0
Dividends declared (10,179) 0 0 0 (10,179) 0 0
Purchases of treasury stock (1,487) $ 0 (1,487) 0 0 0 0
Purchases of treasury stock (in shares)   (10)          
Stock-based compensation plans and other 976 $ 0 36 940 0 0 0
Stock-based compensation plans and other (in shares)   11          
Change in noncontrolling interest 5 $ 0 0 0 0 0 5
Ending balance at Dec. 31, 2022 17,287 $ 18 (4,594) 19,245 4,784 (2,199) 33
Ending balance (in shares) at Dec. 31, 2022   1,769          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,863 $ 0 0 0 4,863 0 0
Other comprehensive income, net of tax (106) 0 0 0 0 (106) 0
Dividends declared (10,647) 0 0 0 (10,647) 0 0
Purchases of treasury stock (1,978) $ 0 (1,978) 0 0 0 0
Purchases of treasury stock (in shares)   (12)          
Stock-based compensation plans and other 974 $ 0 39 935 0 0 0
Stock-based compensation plans and other (in shares)   9          
Change in noncontrolling interest 4 $ 0 0 0 0 0 4
Ending balance at Dec. 31, 2023 $ 10,397 $ 18 $ (6,533) $ 20,180 $ (1,000) $ (2,305) $ 37
Ending balance (in shares) at Dec. 31, 2023   1,766